Immune Thrombocytopenia in Patients with Chronic Lymphocytic Leukemia Is Associated with Stereotyped B-cell Receptors

Carlo Visco(University of Verona), Agostino Cortelezzi(Istituti di Ricovero e Cura a Carattere Scientifico), Elisabetta Novella(Ospedale San Bortolo), Gianluigi Reda(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Giacomo Tuana(University of Messina), Wilma Barcellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Antonino Neri(University of Milan), Marta Lionetti(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Sonia Fabris(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Ilaria Giaretta(University of Milan), Luca Baldini(University of Milan), Francesco Rodeghiero(Ospedale San Bortolo), Francesco Maura(Memorial Sloan Kettering Cancer Center), Luca Agnelli(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico)
Clinical Cancer Research
February 10, 2012
10.1158/1078-0432.ccr-11-3019
Cited by 30

Related Papers

Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group
|Blood|2008|2.6k
International Myeloma Working Group molecular classification of multiple myeloma: spotlight review
|Leukemia|2009|877
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682